

Effective Dosing of Burosumab in XLH

NCT07183579

Status RECRUITING
Sponsor University of Nottingham
Enrollment 120 participants

Key Eligibility Criteria

Inclusion (2)

- A diagnosis of x-linked hypophosphataemia (XLH) including genetic confirmation of a PHEX mutation.
- Has received at least 12 months of continuous Burosumab treatment under paediatric criteria (given Burosumab is not started till a child is 12 months old in England, the minimum age will, therefore, be 2 years old) prior to their 18th birthday.

Exclusion (1)

- Burosumab received under adult criteria (patients who have received both Burosumab under paediatric arrangements and, subsequently, adult arrangements, can have data obtained during paediatric dosing included).

Locations (1 total)

Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom